Abstract
PURPOSE OF REVIEW: Myxoid/round cell liposarcoma (MRCL) represents about 10% of all soft-tissue sarcomas. Therapeutic options for this subgroup of tumours are limited, essentially doxorubicin-based regimens and trabectedin. Recently, the mammalian target of rapamycin (mTOR) pathway has been identified as a therapeutic target in several sarcomas. MRCLs should be included among these, as various molecular aberrations of the mTOR pathway have been recently reported. RECENT FINDINGS: PI3KCA mutations were identified in 10-20% of MRCLs. Other molecular aberrations include loss of PTEN, Akt activation and overexpression of IGF1R. Recently, two minor responses to mTOR inhibitors were reported. SUMMARY: The relatively high frequency of mTOR signalling pathway alterations in MRCL provides a preclinical rationale for considering mTOR inhibition as a potential novel therapeutic strategy warranting further investigation.
Original language | English |
---|---|
Pages (from-to) | 379-383 |
Number of pages | 5 |
Journal | Current Opinion in Oncology |
Volume | 25 |
Issue number | 4 |
DOIs | |
Publication status | Published - Jul 2013 |
Keywords
- drug therapy
- mTOR
- myxoid/round cell liposarcoma
- PI3K/Akt pathway
- soft-tissue sarcoma
ASJC Scopus subject areas
- Cancer Research
- Oncology